Table I.
Clinical characteristics of patients with non-small cell lung cancer with anaplastic lymphoma kinase fusion (n=64).
| p-c-Kit level | p-PDGFRA detection | ||||||
|---|---|---|---|---|---|---|---|
| Characteristic | n (%) | High, % | Low, % | P-value | Positive, % | Negative, % | P-value |
| Age, years | 0.03a | 0.38 | |||||
| ≥52 | 33 (51.6) | 12, 36.4 | 21, 63.6 | 7, 21.2 | 26, 78.8 | ||
| <52 | 31 (48.4) | 4, 12.9 | 27, 87.1 | 4, 12.9 | 27, 87.1 | ||
| Sex | 0.77 | 0.30 | |||||
| Male | 38 (59.4) | 10, 26.3 | 28, 73.7 | 5, 13.2 | 33, 86.8 | ||
| Female | 26 (40.6) | 6, 23.1 | 20, 76.9 | 6, 23.1 | 20, 76.9 | ||
| TKI treatment | 1.0 | 0.93 | |||||
| Crizotinib | 41 (64.1) | 11, 26.8 | 30, 73.2 | 8, 19.5 | 33, 80.5 | ||
| No TKI treatment | 23 (35.9) | 5, 21.7 | 18, 78.3 | 3, 13.0 | 20, 87.0 | ||
| Line of TKI treatment (n=41) | 0.38 | 0.62 | |||||
| First-line | 25 (61.0) | 5, 20.0 | 20, 80.0 | 6, 24.0 | 19, 76.0 | ||
| Second-line and above | 16 (39.0) | 6, 37.5 | 10, 62.5 | 2, 12.5 | 14, 87.5 | ||
| Brain metastasis | 0.77 | 0.01a | |||||
| Yes | 26 (40.6) | 7, 26.9 | 19, 73.1 | 9, 34.6 | 17, 65.4 | ||
| No | 38 (59.4) | 9, 23.7 | 29, 76.3 | 2, 5.3 | 36, 94.7 | ||
| Time of brain metastasis (n=26) | 1.0 | 0.63 | |||||
| Incipient | 20 (76.9) | 5, 25.0 | 15, 75.0 | 7, 35.0 | 13, 65.0 | ||
| During TKI treatment | 6 (23.1) | 2, 33.3 | 4, 66.7 | 1, 16.7 | 5, 83.3 | ||
| Symptoms of brain metastasis (n=26) | 1.0 | 0.67 | |||||
| Yes | 7 (26.9) | 2, 28.6 | 5, 71.4 | 3, 42.9 | 4, 57.1 | ||
| No | 19 (72.1) | 5, 26.3 | 14, 73.7 | 6, 31.6 | 13, 68.4 | ||
| Response to crizotinib (n=41) | 0.99 | 1.0 | |||||
| Partial response rate | 28 (68.2) | 7, 25.0 | 21, 75.0 | 5, 17.9 | 23, 82.1 | ||
| Stable disease rate | 9 (22.0) | 2, 22.2 | 7, 77.8 | 2, 22.2 | 7, 77.8 | ||
| Disease progression rate | 4 (9.8) | 2, 50.0 | 2, 50.0 | 1, 25.0 | 3, 75.0 | ||
| Overall survival rate* (n=64) | n=16 | n=48 | NA | n=11 | n=53 | NA | |
| Percent of patients alive at one year | 51, 79.6 | 10, 60.0 | 41, 86.0 | 8, 73.0 | 43, 81.0 | ||
| Percent of patients alive at three year | 37, 57.8 | 4, 25.0 | 33, 69.0 | 4, 36.0 | 33, 62.0 | ||
a
P<0.05. p-c-Kit, phosphorylated mast/stem cell growth factor receptor kit; p-PDGFRA, phosphorylated platelet-derived growth factor receptor α; TKI, tyrosine kinase inhibitor; NA, not available. *Overall survival rate refers to cumulative survival at one or three-year, calculated using Kaplan-Meier method. Data represent the ratio of the number of patients alive at one or three-year to the total number of patients among the different groups.